You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.
SBC: Boston Immune Technologies And Therapeutics Inc. Topic: NIAIDPROJECT SUMMARY Sjögren’s syndrome (SjS) is a highly disabling systemic autoimmune disease. Symptoms include mucosal dryness (as a result of the destruction of the epithelium of exocrine glands, mainly the salivary and lacrimal glands), pain, and fatigue. Moreover, 30-50% of patients risk systemic and potentially lethal complications. Candidate therapeutics for the disease over the past 20 year ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of antibody drug conjugates as pan-filo antivirals
SBC: MICROBIOTIX, INC. Topic: NIAIDProject Summary Filoviruses cause severe hemorrhagic fevers and are among the deadliest human viruses with no approved treatment or prophylactic options. Periodic outbreaks, such as the recent epidemic of Ebola virus (EBOV) in West Africa, exhibit mortality rates ranging from 50-90%. They are classified as “Category A priority bioweapon agents” by the Centers for Disease Control and Prevention ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
IL-17A mRNA-targeted oligonucleotide therapeutics in Idiopathic Pulmonary Fibrosis (IPF)
SBC: TARGETSITE THERAPEUTICS CORPORATION Topic: NHLBIAbstract. Idiopathic pulmonary fibrosis (IPF) is a progressive fibroproliferative disorder affecting ∼3 million people worldwide with function-limiting progressive symptoms and a 2-3 year median survival time from diagnosis. While the etiology of IPF is not clear, genetic factors, environmental exposures and microbial pathogens have been identified as IPF risk factors. Pirfenidone and nintedanib ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Active Low-Voltage Modulators
SBC: PHYSICAL SCIENCES INC. Topic: N231010We propose the development of Active Low-Voltage Modulators (ALVM) based on the thin film lithium niobate (TFLN) photonic-integrated circuit (PIC) platform to realize enhanced radio-frequency (RF) links that are compact, efficient, and can be scalably manufactured using a commercial wafer-scale production capability. The proposed modulator design combines a semiconductor optical amplifier (SOA) wi ...
SBIR Phase I 2023 Department of DefenseNavy -
Acoustic Internal Automated Concrete Tie Tester
SBC: NDT CORPORATION Topic: 23FR1NDT Corp. will take the currently developed ACTT system, which can accurately assess the internal condition of concrete crossties and increase its speed.FRA 23-FR1 requests a system that at high speeds can assess both the internal and external condition of concrete crossties.Currently there are systems that can perform the external assessment at the required speeds.However, there is no system that ...
SBIR Phase I 2023 Department of Transportation -
SBIR Phase I:Continuous, Scalable Crystallizer for Pharmaceutical Manufacturing
SBC: Zaiput Flow Technologies LLC Topic: CTThe broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to improve a key step used in the greater than$500-billion market of pharmaceutical manufacturing: purification of active pharmaceutical ingredients. Ninety percent of all active pharmaceutical ingredients are purified using crystallization, however, current approaches to crystallization ha ...
SBIR Phase I 2023 National Science Foundation -
SBIR Phase I: Optimization and scaling of ladder polymers for membrane-based gas separations
SBC: Osmoses Inc. Topic: CTThis broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project aims to develop membrane solutions to address opportunities in the gas and vapor separation market. Today, this market is dominated by energy-intensive thermal processes that have large carbon footprints, such as distillation and absorption/stripping. The current membrane solutions often lack ...
SBIR Phase I 2023 National Science Foundation -
SBIR Phase I:Predictive Analytics and Machine Learning Modeling for New Patient Cancer Referrals
SBC: IIAM CORPORATION Topic: DHThe broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to decrease patient referral wait times. Referral wait times are often long since offices need to retrieve a large amount of medical information on a patient before they are seen by a doctor. Unfortunately, medical records are often not stored in one place, making it difficult to gather the ...
SBIR Phase I 2023 National Science Foundation -
Launchable Mini Glider for Variable Payloads
SBC: TRITON SYSTEMS, INC. Topic: N231032In response to N231-032, Launchable Mini Glider for Variable Payloads, Triton Ocean Systems will provide an open architecture subsea sensor platform based on Triton’s proven low-cost ocean tools: (1) the expendable subDART glider, (2) the LIMBIC inertial navigation system, (3) the openORB surface buoy, (4) the PBOF rotary actuator, (5) the BEM extreme-low-cost buoyancy engine module. Triton has ...
SBIR Phase I 2023 Department of DefenseNavy -
Computationally-Inspired Design of Non-Viral Gene Delivery Vehicles for mRNA-Based Cystic Fibrosis Therapies
SBC: NANITE INC. Topic: NHLBIPROJECT SUMMARY Cystic fibrosis (CF) is a debilitating and life-shortening disease affecting more than 70,000 people worldwide, with ~1,000 new cases expected to be diagnosed every year. This disease is an autosomal recessive genetic disorder associated with mutations in the CF transmembrane conductance regulator (CFTR). These mutations impairs the ionic transport across the cell membrane. In the ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health